NCT01929226View on ClinicalTrials.gov

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 9, 2013

Primary Completion Date

November 29, 2013

Study Completion Date

November 29, 2013

Conditions
Inhalational Anthrax
Interventions
BIOLOGICAL

ETI-204

Monoclonal Antibody

OTHER

Placebo

Placebo for ETI-204

Trial Locations (1)

75247

Covance Clinical Research Inc., Dallas

Sponsors
All Listed Sponsors
lead

Elusys Therapeutics

OTHER

NCT01929226 - Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers | Biotech Hunter | Biotech Hunter